Plus Therapeutics (PSTV) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this developer of cell therapies would post a loss of $0.09 per share when it actually produced a loss of $0.01, delivering a surprise of +88.89%.Over the last four quarter ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Grifols (GRFS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Grifols is one of 954 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the aver ...

Indivior PLC (INDV) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +89.47%. A quarter ago, it was expected that this company would post earnings of $0.26 per share when it actually produced earnings of $0.51, delivering a surprise of +96.15%.Over the last four quarters, the company h ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +30.77%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.18 per share when it actually produced earnings of $0.25, delivering a surprise of +38.89%.Over the last fou ...

核心观点 - 公司预计在2025年第三季度出现收入增长但盈利同比下降的局面 实际业绩与市场预期的对比将影响其短期股价 [1] - 公司不太可能实现盈利超预期 其盈利ESP为负值且历史超预期记录不佳 [12][13][14][17] - 同行业公司则因积极的盈利ESP和评级 更有可能实现盈利超预期 [18][19][20] 公司业绩预期 - 预计季度每股亏损为0.36美元 同比恶化16.1% [3] - 预计季度收入为785万美元 同比增长19.9% [3] - 过去30天内 季度每股亏损共识预期被下调4.08% [4] 盈利预测指标 - 盈利预期惊喜（Earnings ESP）为-1.41% 表明分析师近期对其盈利前景转趋悲观 [12] - 公司的Zacks评级为第3级（持有） [12] - 盈利ESP为负值与第3级评级结合 难以预测其将超越盈利预期 [12] 历史表现 - 上一季度实际每股亏损0.35美元 低于预期的0.32美元 出现负惊喜-9.38% [13] - 在过去四个季度中 公司仅一次超越每股盈利预期 [14] 行业对比 - 同行业公司预计季度每股亏损为1.99美元 但同比改善59.6% [18] - 预计季度收入为2.4915亿美元 同比增长300.8% [19] - 其盈利ESP为+27.84% Zacks评级为第2级（买入） 结合其过去四个季度均超预期的历史 很可能再次超越盈利预期 [19][20]

Wall Street expects a year-over-year decline in earnings on lower revenues when NewAmsterdam Pharma Company N.V. (NAMS) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +46.96%. A quarter ago, it was expected that this drug discovery and development company would post earnings of $0.27 per share when it actually produced earnings of $0.86, delivering a surprise of +218.52%.Over th ...

United Therapeutics (UTHR) came out with quarterly earnings of $7.16 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.92%. A quarter ago, it was expected that this drugmaker would post earnings of $6.8 per share when it actually produced earnings of $6.41, delivering a surprise of -5.74%.Over the last four quarters, the com ...

公司业绩预期 - 华尔街预计Madrigal在截至2025年9月的季度营收将实现同比增长，并伴随盈利改善 [1] - 公司预计季度每股亏损为1.99美元，同比改善59.6% [3] - 公司预计季度营收为2.4915亿美元，同比增长300.8% [3] 预期修正趋势 - 过去30天内，该季度共识每股收益预期被上调了10.44%至当前水平 [4] - 最准确预期高于Zacks共识预期，表明分析师近期对公司盈利前景转为乐观 [12] - 这导致公司的盈利ESP为+27.84% [12] 盈利惊喜预测 - 盈利ESP理论上指示实际盈利与共识预期的可能偏差 [9] - 当盈利ESP为正值且结合Zacks排名第1、2或3时，是盈利超预期的强预测指标 [10] - 具有此组合的股票有近70%的概率实现正面惊喜 [10] - Madrigal目前Zacks排名为第2级 [12] - 该组合表明Madrigal极有可能超越共识每股收益预期 [12] 历史惊喜记录 - 上一报告季度，Madrigal预计每股亏损3.48美元，实际亏损1.90美元，实现惊喜+45.40% [13] - 在过去四个季度中，公司四次超越共识每股收益预期 [14] 行业同业比较 - 同业公司BioCryst Pharmaceuticals预计季度每股收益为0.07美元，同比增长200% [18] - 该公司预计季度营收为1.6115亿美元，同比增长37.6% [19] - 过去30天内，其共识每股收益预期被下调4.8% [19] - 该公司盈利ESP为+17.12%，结合其Zacks排名第3级，表明其很可能超越盈利预期 [20] - 在过去四个季度中，该公司两次超越共识每股收益预期 [20]

OmniAb, Inc. (OABI) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Novemb ...